The identification of molecular indicators of higher risk for specific subgroups of cancer patients may allow to develop more aggressive therapeutic strategies aimed at cases with the highest likelihood of response. This would avoid unnecessary toxicity to patients and alleviate the burden of cancer care for healthcare systems. Activated oncogenes and mutated tumor suppressor genes are causal determinants of the appearance and progression of tumors in man. They therefore represent potential indicators of prognosis and/or response to therapy. However, even in cases of well-studied oncogenes and tumor suppressor genes such as TP53 and RAS, their attributed prognostic and predictive value is often based on studies of insufficient statistical power that often lead to conflicting conclusions. Findings in favor or against the use of TP53 and RAS as prognostic and predictive indicators in breast cancer are reviewed and discussed here.
GuerraE., AlbertiS.Molecular prognostic indicators for breast cancer. Tumori2001; 87: 23–5.
2.
NasrA.F., NutiniM., PalomboB., GuerraE., AlbertiS.Mutations of TP53 induce loss of DNA methylation and amplification of the TROP1 gene. Oncogene2003 (in press).
3.
AgamiR., BernardsR.Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell2000; 102: 55–66.
4.
HainautP., HernandezT., RobinsonA.. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res1998; 26: 205–13.
5.
IsolaJ., VisakorpiT., HolliK., KallioniemiO.P.Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst1992; 84: 1109–14.
6.
SilvestriniR., BeniniE., DaidoneM.G.. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst1993; 85: 965–70.
7.
O'ConnorP.M., JackmanJ., BaeI.. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res1997; 57: 4285–300.
8.
BurkeH.B., HoangA., IglehartJ.D., MarksJR. Predicting response to adjuvant and radiation therapy in patients with early stage carcinoma. Cancer1998; 82: 874–7.
9.
ThorA.D., MooreD.H.I., EdgertonS.M.. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst1992; 84: 845–55.
10.
MazarsR., SpinardiL., BenCheikhM., Simony-LafontaineJ., JeanteurP., TheilletC.p53 mutations occur in aggressive breast cancer. Cancer Res1992; 52: 3918–23.
11.
MollU.M., RiouG., LevineA.J.Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA1992; 89: 7262–6.
12.
AndersenT.I., HolmR., NeslandJ.M., HeimdalK.R., OttestadL., BorresenA.L.Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer1993; 68: 540–8.
13.
HurlimannJ., ChaubertP., BenhattarJ.p53 gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. Mod Pathol1994; 7: 423–8.
14.
FailleA., De CremouxP., ExtraJ.M.. p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer1994; 69: 1145–50.
15.
IacopettaB., GrieuF., PowellB., SoongR., McCaulK., SeshadriR.Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin Cancer Res1998; 4: 1597–602.
16.
HartmannA., BlaszykH., McGovernR.M.. p53 gene mutations inside and outside of exons 5–8: the patterns differ in breast and other cancers. Oncogene1995; 10: 681–8.
17.
BorresenA.L., AndersenT.I., EyfjordJ.E.. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer1995; 14: 71–5.
18.
CaseyG., LopezM.E., RamosJ.C.. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene1996; 13: 1971–81.
19.
KovachJ.S., HartmannA., BlaszykH., CunninghamJ., SchaidD., SommerS.S.Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA1996; 93: 1093–6.
20.
BlaszykH., HartmannA., CunninghamJ.M.. A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome. Int J Cancer2000; 89: 32–8.
21.
LaiH., LinL., NadjiM., LaiS., TrapidoE., MengL.Mutations in the p53 tumor suppressor gene and early onset breast cancer. Cancer Biol Ther2002; 1: 31–6; discussion 37–8.
22.
PowellB., SoongR., IacopettaB., SeshadriR., SmithD.R.Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res2000; 6: 443–51.
23.
BernsE.M., FoekensJ.A., VossenR.. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res2000; 60: 2155–62.
24.
KandelR., LiS.Q., OzcelikH., RohanT.p53 protein accumulation and mutations in normal and benign breast tissue. Int J Cancer2000; 87: 73–8.
25.
BianchiS., CalzolariA., VazzosiV.. Lack of prognostic value of p53 protein expression in node-negative breast cancer. Tumori1997; 83: 669–72.
26.
WenW.H., BernsteinL., LescallettJ.. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. Cancer Res2000; 60: 2716–22.
27.
AhrendtS.A., HalachmiS., ChowJ.T.. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci USA1999; 96: 7382–7.
28.
TonissonN., ZernantJ., KurgA.. Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. Proc Natl Acad Sci USA2002; 99: 5503–8.
29.
von LintigF.C., DreilingerA.D., VarkiN.M., WallaceA.M., CasteelD.E., BossG.R.Ras activation in human breast cancer. Breast Cancer Res Treat2000; 62: 51–62.
30.
HokaiwadoN., AsamotoM., ChoY.M., ImaidaK., ShiraiT.Frequent c-Ha-ras gene mutations in rat mammary carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Lett2001; 163: 187–90.
31.
SpandidosD.A.Oncogene activation in malignant transformation: a study of H-ras in human breast cancer. Anticancer Res1987; 7: 991–6.
32.
YanezL., GroffenJ., ValenzuelaD.M.c-K-ras mutations in human carcinomas occur preferentially in codon 12. Oncogene1987; 1: 315–8.
33.
BiunnoI., PozziM.R., PierottiM.A., PilottiS., CattorettiG., Della PortaG.Structure and expression of oncogenes in surgical specimens of human breast carcinomas. Br J Cancer1988; 57: 464–8.
34.
RochlitzC.F., ScottG.K., DodsonJ.M.. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res1989; 49: 357–60.
35.
CapellaG., Cronauer-MitraS., PienadoM.A., PeruchoM.Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ Health Perspect1991; 93: 125–31.
36.
MiyakisS., SourvinosG., SpandidosD.A.Differential expression and mutation of the ras family genes in human breast cancer. Biochem Biophys Res Commun1998; 251: 609–12.
37.
BosJ.L.Ras oncogenes in human cancer: a review. Cancer Res1989; 49: 4682–9.
38.
WardR., HawkinsN., O'GradyR.. Restriction endonuclease-mediated selective polymerase chain reaction: a novel assay for the detection of K-ras mutations in clinical samples. Am J Pathol1998; 153: 373–9.
39.
SchondorfT., AndrackA., NiederacherD.. H-ras gene amplification or mutation is not common in human primary breast cancer. Oncol Rep1999; 6: 1029–33.
40.
von LintigF.C., DreilingerA.D., VarkiN.M., WallaceA.M., CasteelD.E., BossG.R.Ras activation in human breast cancer. Breast Cancer Res Treat2000; 62: 51–62.
41.
McGuireW.L.Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst1991; 83: 154–5.
42.
AlonU., BarkaiN., NottermanD.A.. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci USA1999; 96: 6745–50.
43.
KrausM.H., YuasaY., AaronsonS.A.A position 12-activated H-ras oncogene in all HS578T mammary carcinosarcoma cells but not normal mammary cells of the same patient. Proc Natl Acad Sci USA1984; 81: 5384–8.
44.
ProsperiM.T., DupreG., LidereauR., GoubinG.Point mutation at codon 12 of the Ki-ras gene in a primary breast carcinoma and the MDA-MB-134 human mammary carcinoma cell line. Cancer Lett1990; 51: 169–74.
45.
KannanK., KrishnamurthyJ., FengJ., NakajimaT., TsuchidaN., ShanmugamG.Mutation profile of the p53, fhit, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas. Int J Oncol2000; 17: 1031–5.
